Riegel W, Hörl W H, Heidland A
Klin Wochenschr. 1986 Oct 31;64(21):1124-30. doi: 10.1007/BF01726873.
To evaluate long-term effects of nifedipine on carbohydrate and lipid metabolism, 15 hypertensive patients undergoing regular hemodialysis treatment were investigated before nifedipine therapy, after 3 and 9 weeks, and 2 weeks after stopping nifedipine therapy. Three weeks following the administration of nifedipine, both glucose and insulin concentrations decreased significantly from 102.1 +/- 2.6 to 94.9 +/- 2.2 mg/dl and from 19.9 +/- 2.9 to 13.9 +/- 1.7 microU/ml and also remained significantly lower after 9 weeks of nifedipine therapy. This effect was paralleled by a fall of noradrenaline and dopamine. Glucagon levels remained constant. Glucose tolerance tests performed during nifedipine medication and 2 weeks after stopping of nifedipine therapy did not differ significantly. An increase of pyruvate, citric acid cycle intermediates, and ketone bodies--but not of lactate--was registered during nifedipine medication. The observed effects were not completely abolished after the 2-week placebo phase. Our data indicate that nifedipine lowers serum glucose values despite decreased insulin and constant glucagon levels in hypertensive hemodialyzed patients. Considering additionally the behavior of catecholamines and organic acids, the effects could be explained by the improvement of peripheral glucose utilization.
为评估硝苯地平对碳水化合物和脂质代谢的长期影响,对15例接受常规血液透析治疗的高血压患者在硝苯地平治疗前、治疗3周和9周后以及停止硝苯地平治疗2周后进行了调查。硝苯地平给药3周后,血糖和胰岛素浓度均显著下降,分别从102.1±2.6降至94.9±2.2mg/dl,从19.9±2.9降至13.9±1.7μU/ml,且在硝苯地平治疗9周后仍显著降低。去甲肾上腺素和多巴胺水平下降与这种效应平行。胰高血糖素水平保持不变。在硝苯地平用药期间及停药2周后进行的葡萄糖耐量试验无显著差异。硝苯地平用药期间丙酮酸、柠檬酸循环中间产物和酮体增加,但乳酸未增加。在为期2周的安慰剂阶段后,观察到的效应并未完全消除。我们的数据表明,在高血压血液透析患者中,尽管胰岛素水平降低且胰高血糖素水平恒定,但硝苯地平仍能降低血清葡萄糖值。此外,考虑到儿茶酚胺和有机酸的变化,这些效应可以用外周葡萄糖利用的改善来解释。